Alzheimer's Disease Neuroimmune Resolution and Specialized Pro-Resolving Mediator Companies

AD Neuroimmune Resolution SPM Companies

Overview

AD Neuroimmune Resolution SPM Companies

Overview

This category page covers biotechnology and pharmaceutical companies developing neuroimmune resolution therapies, specialized pro-resolving mediator (SPM) approaches, and pro-resolving cytokine modulators for Alzheimer's disease. Chronic neuroinflammation is a core pathological feature of AD, characterized by ongoing activation of microglia and astrocytes. SPMs — including resolvins, protectins, maresins, and lipoxins — represent a novel therapeutic approach that actively promotes resolution of inflammation rather than simply suppressing it.

Companies targeting this pathway aim to shift the brain's immune state from chronic inflammation to active resolution, protecting neurons, preserving synaptic function, and potentially slowing disease progression.

Key Therapeutic Approaches

| Approach | Description | Companies |
|----------|-------------|-----------|
| SPM Receptor Agonists | Activate G-protein coupled receptors for SPM signaling | Resolvent Biosciences, Omega-3 developers |
| SPM Mimetics | Synthetic analogs of resolvins, protectins, maresins | Cardiol, Cytos |
| Pro-Resolving Cytokine Modulators | Modulate IL-10, TGF-beta for resolution | INmune Bio, Alector |
| NLRP3 Inhibitors | Block inflammasome activation upstream | Nodthera, Cyclo Therapeutics |
| TREM2 Modulators | Enhance microglial phagocytosis and resolution | Alector (AL002), TrueBinding |
| CD47-SIRPalpha Blockade | Enable phagocytic clearance of debris | TrueBinding (TB-006) |

Specialized Pro-Resolving Mediator Companies

Resolvent Biosciences

• Focus: SPM receptor agonists for neuroinflammation resolution
• Mechanism: Develops synthetic resolvins and protectins that activate G-protein coupled receptors (ALX/FPR2, GPR32) to trigger active inflammation resolution
• Indication: Alzheimer's disease, other neurodegenerative conditions
• Stage: Research/lead optimization
• Notes: Pioneer in SPM receptor pharmacology; platform spans multiple SPM analogs and receptor targets
• Key Targets: ALX/FPR2, GPR32, resolvin D1, resolvin D2, protectin D1

Cardiol Therapeutics

• Focus: SPM mimetics and anti-inflammatory approaches
• Lead Candidate: CardiolRx (CBD formulation)
• Mechanism: Anti-inflammatory properties through multiple pathways including SPM promotion; modulates neuroimmune response
• Indication: Alzheimer's disease, cardiac inflammation
• Stage: Phase 2 (cardiac), preclinical (AD)
• Notes: Leverages anti-inflammatory properties of cannabinoids for neuroimmune modulation
• Key Targets: CB2 receptor, inflammatory cytokines, SPM pathways

Cytos Biotechnology

• Focus: SPM mimetics and immunomodulation
• Mechanism: Developing synthetic SPM analogs for enhanced stability and potency compared to endogenous SPMs
• Indication: Alzheimer's disease, inflammatory conditions
• Stage: Research
• Notes: Swiss biotech with expertise in immunomodulatory approaches
• Key Targets: SPM receptors, inflammatory resolution

Neuroimmune Resolution Companies

INmune Bio

• Focus: Pro-resolving cytokine and complement modulation
• Lead Candidate: XPro1595 (DN-TNF inhibitor)
• Mechanism: Selective inhibition of soluble TNF (not membrane TNF) to reduce neuroinflammation while preserving immune surveillance; promotes pro-resolving state
• Indication: Alzheimer's disease
• Stage: Phase 2
• Notes: Phase 1 data showed reduction in neuroinflammatory biomarkers. Novel approach targeting chronic inflammation without suppressing normal immune function
• Clinical Trials: Phase 2 in AD patients with elevated inflammatory markers
• Key Targets: Soluble TNF, neuroinflammation, cognitive function

Nodthera

• Focus: NLRP3 inflammasome inhibitors
• Lead Candidate: NT-0796
• Mechanism: Oral NLRP3 inhibitor blocking upstream inflammasome activation; reduces IL-1beta and IL-18 production
• Indication: Alzheimer's disease, inflammatory diseases
• Stage: Phase 1
• Notes: First oral NLRP3 inhibitor to enter the clinic for AD; addresses upstream driver of chronic neuroinflammation
• Key Targets: NLRP3, IL-1beta, IL-18, inflammasome

Cyclo Therapeutics

• Focus: NLRP3 inhibition and metabolic approaches
• Lead Candidate: Trappsol (cyclodextrin)
• Mechanism: Broad anti-inflammatory effects including NLRP3 inhibition; also addresses cholesterol metabolism and lysosomal function
• Indications: Alzheimer's disease, Niemann-Pick disease
• Stage: Phase 2/3 (NPC), Phase 2 (AD planned)
• Notes: Longstanding development for rare diseases now expanding to AD; broad mechanism offers multiple benefits
• Key Targets: NLRP3, lysosomal function, cholesterol transport

Alector

• Focus: TREM2 modulators and neuroimmune checkpoint
• Lead Candidate: AL002 (TREM2 agonist)
• Mechanism: Activates TREM2 on microglia to enhance phagocytic clearance of amyloid and debris; promotes neuroprotective microglial state
• Indication: Alzheimer's disease
• Stage: Phase 2
• Notes: Leading TREM2 program; INteRhYthM trial in early AD. TREM2 variants associated with AD risk, making this a genetically validated target
• Clinical Trials: INteRhYthM Phase 2 study
• Key Targets: TREM2, microglial activation, amyloid clearance

TrueBinding

• Focus: CD47-SIRPalpha blockade for immune clearance
• Lead Candidate: TB-006
• Mechanism: Blocks CD47-SIRPalpha "don't eat me" signal to enable microglial phagocytosis of amyloid plaques and damaged cells
• Indication: Alzheimer's disease
• Stage: Phase 1/2
• Notes: Novel mechanism enabling active clearance; addresses the neuroimmune checkpoint that prevents debris removal
• Key Targets: CD47, SIRPalpha, phagocytic clearance

SPM and Omega-3 Derived Approaches

Multiple Companies Developing SPM-Related Approaches

• Focus: Converting omega-3 fatty acids (EPA, DHA) to SPMs in vivo or delivering SPMs directly
• Mechanism: Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are precursors to resolvins, protectins, and maresins
• Notes: Several approaches:
• High-dose omega-3 to increase endogenous SPM production
• SPM analog delivery (more stable than endogenous compounds)
• Enzyme modulators to enhance SPM conversion

Pipeline Overview

| Company | Candidate | Mechanism | Stage | Indication |
|---------|-----------|-----------|-------|------------|
| INmune Bio | XPro1595 | Soluble TNF inhibitor | Phase 2 | AD |
| Nodthera | NT-0796 | NLRP3 inhibitor | Phase 1 | AD |
| Alector | AL002 | TREM2 agonist | Phase 2 | AD |
| TrueBinding | TB-006 | CD47 blockade | Phase 1/2 | AD |
| Cyclo | Trappsol | NLRP3/lysosomal | Phase 2 | AD |
| Resolvent | SPM agonists | SPM receptor agonist | Research | AD |
| Cardiol | CardiolRx | SPM promotion | Preclinical | AD |

Scientific Rationale

Neuroinflammation in AD is characterized by:

• Chronic microglial activation surrounding amyloid plaques
• Elevated pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha)
• Reduced anti-inflammatory and pro-resolving mediators
• Impaired phagocytic clearance of amyloid and cellular debris

• Resolvins (from omega-3): Potent pro-resolving mediators
• Protectins (from DHA): Neuroprotective and pro-resolving
• Maresins (from DHA): Promote tissue repair and resolution
• Lipoxins (from arachidonic acid): Endogenous resolution mediators

• Block neutrophil infiltration
• Promote macrophage/microglial phagocytosis
• Reduce cytokine production
• Enhance clearance of cellular debris
• Support tissue repair

References

See Also

• [Neuroinflammation Overview](/mechanisms/neuroinflammation-mechanism) — Chronic brain inflammation in AD/PD
• [TREM2 Protein](/proteins/trem2-protein) — Microglial receptor for amyloid clearance
• [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome-pathway) — Key driver of neuroinflammation
• [Microglia in AD](/cell-types/microglia) — Brain immune cells and neuroinflammation
• [Cytokines in Neurodegeneration](/mechanisms/cytokine-signaling-pathways) — IL-1, TNF, IL-6 signaling
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Target disease
• [Neuroimmune Checkpoint](/mechanisms/neuroimmune-checkpoint-pathology) — CD47-SIRPalpha mechanisms
• [Amyloid Clearance Pathways](/mechanisms/amyloid-clearance-mechanisms) — Phagocytic clearance of Aβ
• [Therapeutics Overview](/therapeutics/therapeutic-approaches) — All therapeutic approaches
• [Clinical Trials](/clinical-trials/clinical-trials-index) — Search neuroimmune trials